Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division

Vista sencilla de ítem
dc.contributor.authorVecchiola, A.
dc.contributor.authorFuentes, C.A.
dc.contributor.authorSolar, I.
dc.contributor.authorLagos, C.F.
dc.contributor.authorOpazo, M.C.
dc.contributor.authorMuñoz-Durango, N.
dc.contributor.authorRiedel, C.A.
dc.contributor.authorOwen, G.I.
dc.contributor.authorKalergis, A.M.
dc.contributor.authorFardella, C.E.
dc.date.accessioned2021-11-26T16:24:35Z
dc.date.available2021-11-26T16:24:35Z
dc.date.issued2020-04
dc.descriptionIndexación: Scopuses
dc.description.abstractIntroduction: Mineralocorticoid receptor (MR) activation within adipose tissue, triggers inflammation and metabolic syndrome development. The pharmacological blockade of MR provides beneficial effects for adipose tissue. Our study evaluates the impact of eplerenone implantation upon obesity. Experimental approach: A group of mice with implanted placebo pellets were fed using two types of diet, a normal (ND) or a high fat (HFD) diet. Additionally, a group of mice fed HFD were implanted with an eplerenone pellet. Metabolic and biochemical parameters were assessed in each animal group. Adipocyte size and lipid accumulation were investigated in the liver and adipose tissue. We evaluated the components of renin-angiotensin-aldosterone system (RAAS) locally in adipose tissue. Key results: Eplerenone reduced HFD-induced body weight gain, fasting glucose levels, fat accumulation, HFD-induced adipocyte size and liver lipid accumulation and improved glucose tolerance. In the adipose tissue, HFD significantly increased the mRNA levels of the RAAS molecules relative to the ND group. Eplerenone lowered RAAS mRNA levels, components of lipid metabolism and markers of inflammation in HFD-fed animals. Conclusion: MR antagonism with eplerenone diminishes insulin resistance that is related to obesity partly via a reduction of RAAS activation, inflammatory progression and cytokines induction. This suggests that eplerenone should be further studied as a therapeutic option for obesity and overweight. © Copyright © 2020 Vecchiola, Fuentes, Solar, Lagos, Opazo, Muñoz-Durango, Riedel, Owen, Kalergis and Fardella.es
dc.description.urihttps://www.frontiersin.org/articles/10.3389/fendo.2020.00223/full
dc.identifier.citationFrontiers in Endocrinology Volume 1121 April 2020 Article number 223es
dc.identifier.doi10.3389/fendo.2020.00223
dc.identifier.issn1664-2392
dc.identifier.urihttp://repositorio.unab.cl/xmlui/handle/ria/21093
dc.language.isoenes
dc.publisherFrontiers Media S.A.es
dc.rights.licenseAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.es
dc.subjectHigh-fat diet animal model.es
dc.subjectRAASes
dc.subjectMineralocorticoid receptor.es
dc.subjectMR antagonists.es
dc.titleEplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Divisiones
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Vecchiola_A_Eplerenone_Implantation_Improved_Adipose_Dysfunction_2020_Article.pdf
Tamaño:
1.17 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLES
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Fac.CV - Artículos de Revista